Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe

Kyle Blankenship

Among the wealth of emerging targets in oncology, immune system suppressing regulatory T cells — better known as “Tregs” — have earned some big-name interest in recent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe

Kyle Blankenship

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Big Phar­ma back­ers jump on board 'Treg' car­tog­ra­pher's lead round with up to six can­di­dates in the pipe

Kyle Blankenship

Sign up to read this article for free.

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

Big Pharma backers jump on board 'Treg' cartographer's lead round with up to six candidates in the pipe

New fund will pressure flailing biotechs, as investor frustration boils over

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence